US Edition
Pfizer, BioNTech Halt US COVID Vaccine Study After Recruitment Struggles
The companies said the study ended because enrollment missed a 25,000-to-30,000 target and was not halted over safety concerns.
- On Wednesday, Pfizer and BioNTech halted a major U.S. clinical trial of their updated COVID-19 vaccine for healthy adults aged 50 to 64, citing insufficient participant enrollment. The companies confirmed the decision is unrelated to any safety concerns.
- Recruitment for the study, which aimed to enroll 25,000 to 30,000 individuals, proved difficult as more than 80% of candidates failed pre-screening. The FDA last year increased requirements for vaccine approvals in the 50–64 age group, demanding large, placebo-controlled trials.
- Moderna is also facing significant recruitment challenges in a similar U.S. study aiming to enroll 30,000 volunteers. Only about 18% of Americans received a COVID booster during the 2025–26 season, reflecting broader industry demand collapse.
- Without the study data, an expected presentation to the FDA's Vaccines and Related Biological Products Advisory Committee likely won't proceed. No COVID-19 vaccines currently hold full clearance for healthy adults aged 50 to 64.
- Vaccine makers continue to grapple with declining revenue as demand falls from pandemic peaks. FDA vaccine chief Vinay Prasad, who pushed for these strict trial standards, is leaving the agency this month.
19 Articles
19 Articles
Pharmaceutical Giant Pfizer Forced To Shut Down Updated COVID Vaccine Trials
My how the tables have turned. It wasn't long ago that Pfizer was viewed and praised as the savior of humanity. Including by their own CEO, Albert Bourla. Just four and a half years ago, governments, politicians, educational institutions and corporations mandated that employees, students, or even those simply entering offices or facilities receive COVID vaccines.These policies were created with the help of experts who treated Pfizer's every word…
EMPTY TRIALS, FADING DEMAND: THE COVID VACCINE LANDSCAPE IS CHANGING
Confidence in COVID-19 vaccines in the United States appears to be shifting, as new developments point to declining public engagement and demand. A halted clinical study by Pfizer and BioNTech—reportedly due to an inability to recruit enough participants—marks a rare moment where a widely recommended vaccine could not generate sufficient interest for ongoing research. This […]
Big Pharma Giants Pfizer and BioNTech Forced to Shut Down COVID-19 Booster Shot Trials After Americans Refuse to Be Guinea Pigs | The Gateway Pundit | by Jim Hᴏft
Major Big Pharma companies have abruptly halted their latest COVID-19 mRNA “booster” trial because they literally couldn’t find enough willing participants.
Pfizer, BioNTech Halt US Study of Updated COVID-19 Vaccine
Pfizer and its German partner BioNTech are ending a clinical trial they agreed to run in 2025 when receiving approval from U.S. authorities for their updated COVID-19 immunization. A BioNTech spokesperson confirmed on April 2 that the companies are halting the trial, which was slated to compare healthy vaccine recipients with placebo controls to evaluate the safety and efficacy of the vaccine. “Notably, this study is not ending as a result of an…
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
